Literature DB >> 11387062

A new-generation stable inducible packaging cell line for lentiviral vectors.

D Farson1, R Witt, R McGuinness, T Dull, M Kelly, J Song, R Radeke, A Bukovsky, A Consiglio, L Naldini.   

Abstract

We have successfully generated and characterized a stable packaging cell line for HIV-1-based vectors. To allow safe production of vector, a minimal packaging construct carrying only the coding sequences of the HIV-1 gag-pol, tat, and rev genes was stably introduced into 293G cells under the control of a Tet(o) minimal promoter. 293G cells express the chimeric Tet(R)/VP16 trans-activator and contain a tetracycline-regulated vesicular stomatitis virus protein G (VSV-G) envelope gene. When the cells were grown in the presence of tetracycline the expression of both HIV-1-derived and VSV-derived packaging functions was suppressed. On induction, approximately 50 ng/ml/24 hr of Gag p24 equivalent of vector was obtained. After introduction of the transfer vector by serial infection, vector could be collected for several days with a transduction efficiency similar or superior to that of vector produced by transient transfection both for dividing and growth-arrested cells. The vector could be effectively concentrated to titers reaching 10(9) transducing units/ml and allowed for efficient delivery and stable expression of a GFP transgene in the mouse brain. The packaging cell line and all vector producer clones described here were shown to be free from replication-competent recombinants, and from recombinants between packaging and vector constructs that transfer the viral gag-pol genes. The packaging cell line and the assays developed will advance lentiviral vectors toward the stringent requirements of clinical applications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11387062     DOI: 10.1089/104303401750195935

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  35 in total

1.  A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector.

Authors:  Shuji Kubo; Kohnosuke Mitani
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 2.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Production of lentiviral vectors for transducing cells from the central nervous system.

Authors:  Mingjie Li; Nada Husic; Ying Lin; B Joy Snider
Journal:  J Vis Exp       Date:  2012-05-24       Impact factor: 1.355

Review 4.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

5.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

6.  The beta-catenin binding protein ICAT modulates androgen receptor activity.

Authors:  Ming Zhuo; Chunfang Zhu; JingLucy Sun; William I Weis; Zijie Sun
Journal:  Mol Endocrinol       Date:  2011-09-01

7.  Identification of a novel role of ZMIZ2 protein in regulating the activity of the Wnt/β-catenin signaling pathway.

Authors:  Suk Hyung Lee; Chunfang Zhu; Yue Peng; Daniel T Johnson; Lynn Lehmann; Zijie Sun
Journal:  J Biol Chem       Date:  2013-10-30       Impact factor: 5.157

8.  Efficient large volume lentiviral vector production using flow electroporation.

Authors:  Scott R Witting; Lin-Hong Li; Aparna Jasti; Cornell Allen; Kenneth Cornetta; James Brady; Rama Shivakumar; Madhusudan V Peshwa
Journal:  Hum Gene Ther       Date:  2011-10-24       Impact factor: 5.695

9.  Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.

Authors:  Carolina Gándara; Valerie Affleck; Elizabeth Ann Stoll
Journal:  Hum Gene Ther Methods       Date:  2018-01-24       Impact factor: 2.396

10.  Design and in vivo characterization of self-inactivating human and non-human lentiviral expression vectors engineered for streptogramin-adjustable transgene expression.

Authors:  Barbara Mitta; Cornelia C Weber; Markus Rimann; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2004-07-16       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.